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Hemodialysate composition and intradialytic metabolic, acid—base and
potassium changes. We compared the effects of dialysate composition
on changes in intermediary metabolites, acid—base balance, and potas-
sium removal during hemodialysis. Patients were dialyzed against
dialysates containing acetate or bicarbonate, each with or without
glucose, in a four—way cross—over study. Dialysates containing acetate
were associated with significant perturbations in intermediary metabo-
lism, including increases in blood citrate, acetoacetate and /3-hydroxy-
butyrate and a decrease in pyruvate. In contrast, bicarbonate—
containing dialysates caused minimal perturbations in intermediary
metabolism. Addition of glucose to the dialysate decreased the changes
in intermediary metabolites; however, the magnitude of this effect was
less than that observed for the change from acetate to bicarbonate. Use
of acetate also resulted in lower post—dialysis blood—concentrations of
base equivalents than obtained with bicarbonate; this difference was
unaffected by the presence or absence of glucose. Although pre- and
post-dialysis potassium concentrations were unaffected by the dialysate
formulation, total potassium removal was significantly greater when
glucose was omitted from the dialysate. Our results suggest that both
bicarbonate and glucose should be included in the dialysate, particu-
larly for those patients whose capacity for metabolism may be limited
because of highly efficient dialysis, intercurrent illness, or starvation.
However, addition of glucose to the dialysate may require a reduction
in dialysate potassium to maintain proper potassium homeostasis.
One of the more significant changes in the practice of
hemodialysis in recent years has been the revival of interest in
using bicarbonate as the base repletion agent in hemodialysate.
Although bicarbonate was used historically for base repletion, it
was almost completely replaced by acetate after the effective-
ness and superior physico-chemical properties of the latter were
demonstrated by Mion et al in 1964 [1]. In the late 1970s,
questions began to arise regarding possible deleterious hemo-
dynamic effects of acetate and its replacement with bicarbonate
was observed to ameliorate adverse symptomatology during
dialysis [2]. However, other studies have failed to show any
benefit of bicarbonate over acetate with respect to hemody-
namic stability, and this remains a controversial issue [3, 4].
Bicarbonate may also be a superior base repletion agent to
acetate from a metabolic point of view. Acetate has been shown
to perturb intermediary metabolism in both infusion studies [5,
6] and during dialysis against acetate-containing dialysates
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[7—91. Such perturbations may impact adversely on base reple-
tion during dialysis. Intermediary metabolites generated subse-
quent to the metabolism of acetate, including acetoacetate and
/3-hydroxybutyrate, are dialyzed from the blood, resulting in a
loss of 'potential' base. Interpretation of some of these studies
is complicated by the use of glucose—free dialysate, since
omission of glucose from the acetate—containing dialysate has
been shown to perturb intermediary metabolism [91.
Changes in acid—base balance and insulin affect the intrabody
distribution of potassium. Potassium can be induced to move
from the extracellular to the intracellular space by increasing
blood pH [10] or plasma insulin concentration [11], while
decreasing blood pH [10] or inhibiting insulin secretion [12]
results in the opposite effect. Consequently, the nature of
acid—base changes, as well as any changes in plasma insulin
secondary to including or excluding glucose from the dialysate,
may impact on the ability of dialysis to maintain potassium
homeostasis.
The present study sought to clarify these issues by examining
the relative impact of the choice of base repletion agent and the
presence or absence of glucose in the dialysate on intermediary
metabolism, acid—base balance and potassium removal during
hemodialysis in a four—way cross-over study.
Methods
Patients
Twelve clinically—stable patients (seven male and five female)
were studied. They ranged in age from 30 to 63 years (mean 48
years) and had been maintained on hemodialysis a mean of 27.6
months (range 2 to 54 months). The etiology of their renal
failure varied and included hypertensive nephrosclerosis (4
patients), diabetic glomerulosclerosis (4 patients), glomerulone-
phritis (2 patients) and pyelonephritis (2 patients). The patients
took a variety of medications including vitamin supplements,
oral phosphate binders and antihypertensive agents; however,
drugs, such as sodium bicarbonate and Shohi's solution, known
to influence acid—base status were discontinued for the period
of the study. Of the four patients with diabetic glomeruloscle-
rosis, two required no hypoglycemic agents while two received
NPH insulin daily (12 and 15 IU, respectively). The diabetic
patients all conformed to the maturity—onset type. The study
was approved by the Human Studies Committee of the Univer-
sity of Louisville and informed consent was obtained from each




Dialysis was performed for 4.5 hours, three times per week
using dialyzers containing 1.0 m2 of 11 sm wall thickness,
regenerated cellulose hollow—fibers (HF100, Cobe Laborato-
ries, Lakewood, Colorado, USA) and Centry II Rx dialysate
delivery systems (Cobe Laboratories). Dialyzers were not
reused. Dialysate was prepared from softened, reverse osmo-
sis, carbon filtered water. The dialysate composition varied
according to the study protocol and contained sodium (135
mmollliter), calcium (1.5 mmollliter), magnesium (0.375
mmollliter), potassium (2 to 3 mmollliter, according to patient
needs), acetate or bicarbonate (both at 35 mmoliliter), and
glucose (0 or 11.1 mmol/liter). The concentrates (Rx 110 and Rx
Ill, Cobe Laboratories) used to prepare the bicarbonate dia-
lysate contained acetic acid (final dialysate concentration 2
mmollliter) to create the dialysate buffer system; neither of
these concentrates contained any additional sodium acetate.
Blood access was either by an arteriovenous fistula, bovine or
Gortex heterograft, or a Hemasite (Renal Systems, Minneapo-
lis, Minnesota, USA). Blood flow rates were set at 200 ml/min
for all patients throughout the study. Anticoagulation was
achieved on an individualized basis using a loading dose and
constant infusion of heparin [13].
Study protocol
All patients were dialyzed for one week on each of four
dialysate formulations, containing acetate, acetate with glu-
cose, bicarbonate, and bicarbonate with glucose, respectively.
The order in which each patient was treated with the four
dialysate formulations was randomly assigned. Pre- and post-
dialysis measurements of acid—base parameters and intermedi-
ary metabolites and dialytic exchange of glucose were obtained
on the third dialysis with each dialysate formulation. In eight of
the patients, all dialyzed against dialysates containing 2
mmollliter potassium, dialytic removal of potassium was also
determined. For all dialyses during which data were collected,
the patients were requested to fast overnight (morning dialyses)
or following a light breakfast (afternoon dialyses); no food was
ingested during dialysis.
Sample collection and analysis
Pre-dialysis blood samples were obtained from the arterial
blood access—line prior to dialysis. At the end of dialysis, the
dialysate flow through the dialyzer was halted and the post-
dialysis blood sample immediately drawn from the arterial
blood line. Dialysis was then terminated in the routine manner.
Samples for blood pH and gases were drawn into heparinized
syringes, placed on ice, and immediately analyzed using a blood
gas analyzer (Model 13-213, Instrumentation Laboratory,
Lexington, Massachusetts, USA). Serum bicarbonate concen-
trations were calculated from pH and pCO2 using the
Henderson—Hasselbaich equation and pK of 6.1. Blood for
electrolytes, urea and glucose was collected in heparinized
syringes, centrifuged immediately and the plasma stored at
—70°C until assayed by routine clinical laboratory methods. Net
urea generation rate was calculated by means of a single—pool
model for urea kinetics and used to estimate hydrogen
ion—generation rate [14]. Plasma acetate was determined enzy-
matically [15] and plasma immunoreactive insulin by radio-
immunoassay (Becton Dickinson, Orangeburg, New York,
USA). Blood for intermediary metabolites was deproteinated
with cold (4°C) perchioric acid immediately following collec-
tion, centrifuged, and the supernatant stored at —70°C until
assayed by enzymatic methods for lactate and pyruvate (kits
826-UV and 726-UV, Sigma Chemical Co., St. Louis, Missouri,
USA), citrate [16], acetoacetate [17] and /3-hydroxybutyrate
[18].
The net transfer of glucose and potassium between blood and
dialysate was determined by graphically integrating serial de-
terminations of the instantaneous flux of solute, th, over the
time of dialysis. The instantaneous flux is given by:
m = QDOCDO — QDICDI
where QD is the dialysate flow rate, CD is the dialysate concen-
tration, and the subscripts i and o refer to the dialyzer inlet and
outlet, respectively. The outlet dialysate flow—rate was mea-
sured by timed volumetric collection. The inlet dialysate
flow—rate was then determined as the outlet flow rate less the
calculated ultrafiltration rate.
Data analysis
Within groups, pre- to post-dialysis changes were evaluated
using Student's t-test for paired data. Pre-dialysis values were
compared between groups by analysis of variance. A two—way
analysis of variance [19] was used to separate and compare the
effect of acetate versus bicarbonate and the effect of including
or excluding glucose on pre- to post-dialysis changes. Changes
were considered statistically significant for P values less than
0.05. Values are given as mean standard deviation for N
observations.
Results
Intradialytic fluid removal was comparable between dialysate
formulations, averaging 2.0 kg, overall. Comparison of pre-
dialysis solute concentrations revealed no differences from one
dialysate formulation to another. Further comparisons showed
that, pre-dialysis, the four patients with diabetic glomerulo-
sclerosis differed from the remaining patients in a manner
consistent with their diabetes. They had increased plasma
glucose concentrations (9.8 3.7 mmollliter vs. 5.4 0.8
mmollliter, P < 0.005), were slightly more acidemic (pH =
7.323 0.039 vs. 7.379 0.038, P < 0.01), and had increased
ratios of blood lactate to blood pyruvate (23.0 9.7 vs. 16.7
4.8, P < 0.05). However, there were no differences in any of the
other parameters measured and pre- to post-dialysis changes
induced by dialysis were similar for both diabetic and non-
diabetic patients. Accordingly, the patients were treated as a
single group in comparing the effects of the four dialysate
formulations.
Changes in acid—base parameters
Changes in arterial pH, blood gases, bicarbonate, and hydro-
gen ion generation rate are indicated by the data in the upper
portion of Table 1, while the P values listed in the lower portion
of the Table reflect the two-way analysis of variance for these
parameters. Also shown in Table 1 are the total pre- and
post-dialysis plasma concentrations of the measured organic
anions, that is, the sum of the concentrations of bicarbonate,
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Table 1. Pre- and post-dialysis blood gas and acid—base parameters
Total organic
pCO2 Bicarbonate PO2 anions





Pre-dialysis 7.346 0.035 37.1 3.8 19.7 2.4 100 15 20.83 2.54 57.3 13.8
Post-dialysis 7.409 0.050a 30.9 35 19.0 2.4 101 16 25.93 2.57a
Acetate + glucose
Pie-dialysis 7.350 0.052 35.7 3.2 19.6 2.5 100 13 20.88 3.05 50.6 12.7
Post-dialysis 7.417 0.056a 30.9 47a 19.4 2.8 93 13 24.66 3.18a
Bicarbonate
Pre-dialysis 7.360 0.059 37.7 3.9 21.0 4.0 101 10 22.18 4.10 53.0 12.3
Post-dialysis 7.482 0.052a 36.3 3.7 26.6 3.0k 97 9 28.71 3.19a
Bicarbonate + glucose
Pre-dialysis 7.383 0.044 38.1 5.1 22.1 2.9 105 13 23.25 2.82 48.4 13.5
Post-dialysis 7.483 0.059a 38.7 4.5 28.2 2.9a 103 9 29.74 2.80a
Acetate vs. bicarbonate
P = 0.0126 P = 0.004 P = 0.001 NS P = 0.0415 NS
Glucose vs. glucose—free
NS NS NS NS NS NS
Data shown as mean SD for N = 12
a Significantly different from pre-dialysis
Table 2. Pre- and post-dialysis concentrations of electrolytes, glucose and insulin
Sodium Potassium Chloride Phosphorus Glucose Insulin
mmol/liter mmollliter mmol/liter mmol/liter mmol/liter mU/liter
Acetate
Pie-dialysis 136 4 5.3 1.1 103 4 2.0 0.6 6.3 1.9 24 25
Post-dialysis 135 3 3.7 o,4 99 3 1.1 0.2a 4.9 l.2a 13 6
Acetate + glucose
Pie-dialysis 136 4 5.0 0.8 103 5 2.0 0.5 7.0 3,1 23 14
Post-dialysis 135 3 3.5 0.3 99 3 1.1 0.2 6.6 2.1 23 12
Bicarbonate
Pre-dialysis 137 4 5.1 1.1 102 5 2.1 0.7 7.1 3.7 27 23
Post-dialysis 135 4 3.7 0.4 95 3 1.1 0.2 5.2 l.3a 14 9
Bicarbonate + glucose
Pre-dialysis 137 4 5.2 1.0 101 5 1.9 0.4 7.1 3.4 19 10
Post-dialysis 136 4 3.7 0.Sa 96 3 1.0 0.2k 6.8 2.4 22 15
Acetate vs. bicarbonate
NS NS NS NS NS NS
Glucose vs. glucose—free
NS NS NS NS P = 0.0400 P = 0.0094
Data shown as mean SD for N = 12
a Significantly different from pre-dialysis
acetate, lactate, pyruvate, citrate, acetoacetate and /3-hydroxy-
butyrate. Changes in this value indicate the gain in base as
'potential' bicarbonate in addition to bicarbonate, per se. All
four dialysate formulations resulted in net base gain by the
patient during dialysis. However, bicarbonate was superior in
this regard as evidenced by significantly greater increases in
pH, bicarbonate, and total organic anions. The addition of
glucose had no impact on changes in acid—base parameters with
either dialysate.
Changes in electrolytes, glucose and insulin
Table 2 presents pre- and post-dialysis concentrations of
sodium, potassium, chloride, phosphorus, glucose, and insulin.
Plasma concentrations of potassium, phosphorus, and chloride
were significantly decreased by dialysis; however, this decrease
was not influenced by the choice of base repletion agent or
whether or not glucose was included in the dialysate. Omission
of glucose from the dialysate resulted in a loss of 30.0 9.2 g of
glucose by the patient and caused statistically significant de-
creases in plasma glucose and insulin in comparison to the use
of glucose—containing dialysate which produced an uptake of
15.8 12.2 g of glucose by the patient (P = 0.0001 compared
with glucose—free). Net glucose transfer and changes in glucose
and insulin were unaffected by the choice of acetate or bicar-
bonate.
The data in Table 3 show the effect of dialysate composition
on dialytic potassium removal in the group of eight patients in
which these measurements were made. While pre- and post-
dialysis plasma potassium concentrations were unaffected by
the dialysate used, the total amount of potassium removed by
dialysis did vary. Substantially more potassium was removed
during those treatments in which glucose was omitted from the
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Table 3. Dialytic removal of potassium, and glucose, pre- and post-dialysis plasma potassium, glucose and insulin,
and pre- and post-dialysis pH in a subgroup of eight patients
Potassium removal
mmo! Plasma Glucose Plasma Plasma
potassium removal glucose insulin
Total Intracellular mmol/!iter g mmol/liter mU/liter pH
Acetate
Pre-dialysis 79.7 20.5 57.2 16.7 5.0 0.7 27.7 5,0 5.9 1.3 28 30 7.365 0.018
Post-dialysis 3.6 0.3a 5.1 1.3 12 5 7.432 0.035a
Acetate + glucose
Pre-dialysis 62.2 19.3 37.3 15.3 4.9 0.6 —18.2 5.9 5.7 1.7 24 12 7.367 0.027
Post-dialysis 3.4 0.2 5.7 1.3 22 8 7.441 0.045a
Bicarbonate
Pre-dialysis 72.0 26.4 48.4 20.1 4.8 1.1 29.3 5.0 6.7 2.7 30 26 7.389 0.050
Post-dialysis 3.5 0.2 4.7 0.7 15 8 7.503 0.042a
Bicarbonate + glucose
Pre-dialysis 54.5 24.1 26.5 14.8 5.3 1.0 —20.6 13.7 6.0 2.2 19 7 7.391 0.048
Post-dialysis 3.5 0.3 5.8 1.3 23 17 7.516 0.037a
Acetate vs. bicarbonate
NS NS NS NS NS NS P = 0.0431
Glucose vs. glucose—free
P = 0.0358 P = 0.0019 NS P = 0.0001 P = 0.0387 P = 0.0219 NS
Data shown as mean SD for N = 8
a Significantly different from pre-dialysis
Table 4. Pre- and post-dialysis blood concentrations of acetate, lactate, pyruvate, citrate, acetoacetate, and /3-hydroxybutyrate
Acetate Lactate Pyruvate Citrate Acetoacetate /3-hydroxybutyrate
/.Lmol/!iter mmol/!iter i.unol/liter ,.unol/liter p_inol/liter j.mol/liter
Acetate
Pre-dialysis 42 20 0.74 0.20 48 23 97 52 98 78 130 297
Post-dialysis 3603 1742k 0.66 0.14 29 12 151 61 691 465 1266 891
Acetate + glucose
Pre-dialysis 43 22 0.73 0.21 40 16 98 66 108 113 125 319
Post-dialysis 3503 2416k 0.63 0.18 28 9 128 43 376 298 638 7l7
Bicarbonate
Pre-dialysis 41 17 0.75 0.19 48 23 95 66 116 155 136 347
Post-dialysis 114 45 0.73 0.28 38 20 114 49 378 264 778 761k
Bicarbonate + glucose
Pre-dialysis 59 41 0.84 0.40 49 29 95 54 85 33 56 62
Post-dialysis 99 45 0.70 0.18 34 15 98 42 218 154 359 343
Acetate vs. bicarbonate
P = 0.0001 NS NS P = 0.0070 P = 0.0096 P = 0.0261
Glucose vs. glucose—free
NS NS NS NS P = 0.01 13 P = 0.0036
Data shown as mean SD for N = 12
a Significantly different from pre-dialysis
dialysate. Glucose—free treatments were also associated with
the dialytic removal of glucose which resulted in decreases in
plasma glucose and insulin, relative to treatments with glucose—
containing dialysates. Although pre- and post-dialysis pH
changes were greater with bicarbonate than with acetate, the
choice of base repletion agent did not have a significant impact
on potassium removal. The contribution of the intracellular
compartment to potassium removal was estimated by using the
value for total body water obtained from the urea kinetic
analysis [14], assuming 42% of total body water to be intracel-
lular, and taking pre- and post-dialysis plasma potassium con-
centrations as representative of extracellular concentrations at
those times. The values for intracellular potassium removal
given in Table 3 were then obtained from a simple mass
balance. Depending on the dialysate formulation, 53% to 72% of
potassium removed was derived from intracellular stores. Al-
though these values are only approximations because of the
assumptions made in the calculations, any errors should be
consistent for a given patient, thereby allowing meaningful
comparisons to be made between dialysate formulations.
Changes in intermediary metabolites
Pre- and post-dialysis blood concentrations of acetate, lac-
tate, pyruvate, citrate, acetoacetate, and /3-hydroxybutyrate
are given in the upper portion of Table 4, and the results of the
two—way analysis of variance for these parameters in the lower
portion. Blood acetate concentrations increased during dialysis
with all four dialysate formulations; however, the increase with
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acetate—containing dialysates was much greater than that with
bicarbonate—containing dialysates. Acetate caused blood citrate
concentrations to increase and blood pyruvate concentrations
to decrease significantly; these changes were reduced by sub-
stituting bicarbonate for acetate. Blood lactate concentrations
were unaffected by the dialysate composition. All dialysate
formulations caused some increase in the blood concentrations
of acetoacetate and /3-hydroxybutyrate. These changes were
greatest with acetate in the absence of glucose, while they were
minimized by the combination of bicarbonate and glucose.
Discussion
The data obtained in this study allow two different stimuli to
intermediary metabolism, infusion of acetate and removal of
glucose, to be compared and contrasted in the circumstance of
dialysis. When acetate is used in the dialysate, buffer repletion
relies on generation of bicarbonate secondary to metabolism of
acetate through complex metabolic pathways, including the
Krebs cycle and oxidative phosphorylation [20]. This involve-
ment of the Krebs cycle is reflected in the increased blood
citrate concentrations seen with dialysis against acetate—con-
taining dialysates (Table 4). The first step in acetate metabolism
is the formation of acetyl coenzyme A. As long as sufficient
oxaloacetate is available for acetylation to citrate, acetate will
enter the Krebs cycle and be metabolized to carbon dioxide and
water. Increased concentrations of acetyl coenzyme A are
known to induce synthesis of oxaloacetate from pyruvate
through pyruvate carboxylase [211 and the decrease in blood
pyruvate concentrations seen with acetate—containing dialy-
sates may reflect this process. However, if these pathways
become overloaded, acetyl coenzyme A will be diverted into
production of acetoacetate and /3-hydroxybutyrate. Indeed, the
increases in acetoacetate and /3-hydroxybutyrate seen in this
and other studies [7—9] suggest that the capacity of the Krebs
cycle to metabolize acetate is exceeded during dialysis. We
have previously reported [6, 22] similar changes in citrate,
pyruvate, acetoacetate, and /3-hydroxybutyrate in studies in
which acetate was infused in the absence of dialysis, suggesting
that these changes reflect acetate metabolism, per Se, and are
not merely a consequence of the dialytic process.
Dialytic removal of glucose can also induce changes in
intermediary metabolism. It has been estimated [9] that removal
of quantities of glucose similar to those found with glucose—free
dialysates in this study (25 to 35 g) will stimulate glycogenolysis
and gluconeogenesis. The relative role of these two processes in
replacing glucose losses will depend on body glycogen stores.
In non-fasting patients glycogen stores will be appreciable;
whereas, with fasting, glycogen stores will decrease and
gluconeogenesis will become progressively more dominant in
sustaining blood glucose levels. The patients in this study fasted
6 to 12 hours and could be expected to have reduced glycogen
stores. Gluconeogenesis from lactate involves the conversion of
pyruvate to oxaloacetate; this oxaloacetate is phosphorylated
to phospho-enol-pyruvate and, thence, via the Embden—
Meyerhof pathway to glucose. Decreases in blood pyruvate [9,
23] and alanine [231 during dialysis against glucose—free,
acetate—containing dialysates have been taken as evidence of
increased gluconeogenesis during dialysis. The observation that
plasma glucose decreases but assumes a new steady state level
early in dialysis with glucose-free dialysate [91 is also sugges-
tive that glucose is derived from either glycogenolysis or
gluconeogenesis, or both. However, as discussed previously,
blood pyruvate may decrease secondary to acetate metabolism,
alone. Although we did not measure blood alanine concentra-
tions in this study, we have previously demonstrated [6, 22] that
blood alanine concentrations also decrease during acetate infu-
sion in the absence of dialysis.
Ketone production is also responsive to the glucagon to
insulin ratio [24], with an increase in the ratio favoring the
formation of acetoacetate and /3-hydroxybutyrate. We did not
measure glucagon levels in this study as they are difficult to
interpret in chronic renal failure because of the presence of an
immuno-reactive precursor of questionable biological activity
[251. However, plasma insulin levels decreased when glucose
was omitted from the dialysate, suggesting an increase in the
glucagon to insulin ratio and enhanced ketogenesis. This mech-
anism most likely exacerbated acetoacetate and f3-hydroxybu-
tyrate formation when acetate was used in the absence of
glucose and may also explain the increases seen when bicar-
bonate was used in the absence of glucose. Small increases in
acetate, acetoacetate and /3-hydroxybutyrate were observed
when bicarbonate was used as the base repletion agent. These
changes are most likely caused by the 2 mmol/liter acetic acid
included in the dialysate to buffer the bicarbonate, rather than
an effect of bicarbonate, per Se.
Consequently, the dialytic loss of glucose and the influx of
acetate might be expected to compete for pyruvate, the combi-
nation of the two maximally perturbing intermediary metabo-
lism. The data in Table 4 support this contention and show
further that, of the two stimuli, acetate has the more profound
effect on intermediary metabolism. In comparison to bicarbon-
ate, use of acetate as the base repletion agent caused signifi-
cantly greater increases in blood levels of acetate, citrate,
acetoacetate, and /3-hydroxybutyrate. Omission of glucose
from the dialysate exacerbated the increases in acetoacetate
and /3-hydroxybutyrate, so that the greatest changes in inter-
mediary metabolism were observed with the use of glucose
free, acetate—containing dialysate and the smallest changes with
the use of dialysate containing both bicarbonate and glucose.
The effect of adding glucose to the dialysate is in general
agreement with previous studies [9, 261, although we did not
observe the decrease in post-dialysis acetate concentration,
relative to glucose-free dialysate, described by Desch et al [26]
for acetate—containing dialysates.
Replenishment of bicarbonate buffer stores depleted by inter-
dialytic acid generation is an important goal of dialysis therapy.
The organic anions which accumulate in the blood during
acetate dialysis represent "potential" bicarbonate and are
removed from the blood by dialysis. At the same time, bicar-
bonate is also lost into the dialysate so that the net accrual of
base by the patient is a balance between the uptake of acetate
and the loss of bicarbonate and organic anions. It has been
speculated [27] that the net accrual of base with acetate dialysis
may be insufficient to meet the goal of neutralizing inter-dialytic
acid production and that this may lead to chronic depletion of
body buffer stores, such as those of bone. Although this
concept remains controversial, it is true that many patients
present for dialysis with a marked metabolic acidosis so that
maximizing net base accrual is an important objective. The data
in Table 1 show that substitution of bicarbonate for acetate as
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the base repletion agent has a significant impact on base
repletion as judged by changes in blood pH and blood levels of
bicarbonate and total organic anions. It is important to consider
total organic anions when interpreting the data obtained with
acetate containing dialysates, as accumulated non-bicarbonate
organic anions will be metabolized to bicarbonate once dialysis
ceases. Including glucose in the dialysate has the further, albeit
relatively minor, effect of reducing blood concentrations and,
hence, dialytic loss of acetoacetate and /3-hydroxybutyrate.
Although the increase in total organic anions during dialysis
in this study was only 1 to 2 mmollliter greater with bicarbon-
ate—containing dialysates than with acetate—containing dialy-
sates (Table 1), the cumulative effect on body buffer stores over
months of dialysis may be significant. The impact may be more
profound in some therapies, such as high efficiency, short time
dialysis. While net acid production remains unchanged, these
therapies require that base repletion must be carried out in a
much shorter time and, therefore, at higher rates of mass
transfer. In the circumstance of dialysis against acetate, the
bidirectional fluxes of acetate and bicarbonate will be increased
leading to increased generation and dialytic loss of acetoacetate
and /3-hydroxybutyrate. This may serve to further compromise
base repletion. The concept of shortening dialysis time by
increasing dialyzer performance was first proposed by Babb et
al in 1972 [28] and several clinical evaluations were performed
in the mid- 1970s [29—31]. Although acid—base data were not
always presented in these reports, two prospective, cross—over
studies [30, 311 showed pre-dialysis serum bicarbonate concen-
trations to be decreased during the period of short time dialysis.
The concept of short time dialysis has recently been revived
[32]. In comparison to earlier studies, both the efficiency of the
dialyzers and the blood flow rates now being used are increased
and an even more profound effect on base repletion might be
expected. For this reason, it would seem prudent to use
bicarbonate-containing dialysates for these therapies. Indeed,
it has been suggested [331 that the use of bicarbonate is a
requirement for adequate acid—base balance in high efficiency,
short time dialysis as practiced today. The additional inclusion
of glucose in the dialysate would also seem warranted, partic-
ularly in patients who may have limited hepatic glycogen stores.
The presence or absence of glucose in the dialysate also
influenced dialytic potassium removal (Table 3), with potassium
removal being greater when glucose was omitted from the
dialysate. Changes in plasma insulin are known to effect redis-
tribution of potassium; inhibition of insulin secretion causes
movement of potassium into the extracellular space [12], while
insulin infusion has the opposite effect [11]. These mechanisms
continue to operate in maturity onset diabetics with normal
insulin levels [121, as was the case with the diabetic patients in
this study. Omission of glucose from the dialysate resulted in
decreased plasma insulin—concentrations (Table 2), which in
turn would enhance egress of potassium from cells and maxi-
mize the potassium available for dialytic removal. That the
additional potassium removed did derive from intracellular
stores is further supported by the observation that pre- to
post-dialysis changes in plasma potassium did not differ from
one dialysate formulation to another. Accordingly, changes in
plasma concentrations are a poor guide to dialytic removal of
potassium and maintenance of proper potassium homeostasis
may depend on selecting an appropriate dialysate concentration
of both glucose and potassium. Changes in acid—base status can
also affect the intracorporeal distribution of potassium [10],
with an increase in pH favoring an intracellular shift of potas-
sium. Use of bicarbonate in the dialysate resulted in signifi-
cantly greater increases in blood pH than were obtained with
acetate (Table 1). However, although there was a tendency for
potassium removal to be less with bicarbonate, the choice of
base repletion agent did not have a statistically significant
impact on potassium removal. This is in general agreement with
previous work by Williams et al [34]. Cases of severe hypoka-
lemia during hemodialysis have been ascribed to dialytic cor-
rection of acidosis [35]; however, the changes in blood pH in
these cases were much greater than observed in our patients.
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